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Abstract
Background: The mutation spectra of the TP53 gene and other tumor suppressors contain multiple hotspots,
i.e., sites of non-random, frequent mutation in tumors and/or the germline. The origin of the hotspots remains
unclear, the general view being that they represent highly mutable nucleotide contexts which likely reflect effects
of different endogenous and exogenous factors shaping the mutation process in specific tissues. The origin of
hotspots is of major importance because it has been suggested that mutable contexts could be used to infer
mechanisms of mutagenesis contributing to tumorigenesis.
Results: Here we apply three independent tests, accounting for non-uniform base compositions in synonymous
and non-synonymous sites, to test whether the hotspots emerge via selection or due to mutational bias. All three
tests consistently indicate that the hotspots in the TP53 gene evolve, primarily, via positive selection. The results
were robust to the elimination of the highly mutable CpG dinucleotides. By contrast, only one, the least
conservative test reveals the signature of positive selection in BRCA1, BRCA2, and p16. Elucidation of the origin
of the hotspots in these genes requires more data on somatic mutations in tumors.
Conclusion: The results of this analysis seem to indicate that positive selection for gain-of-function in tumor
suppressor genes is an important aspect of tumorigenesis, blurring the distinction between tumor suppressors
and oncogenes.
Reviewers: This article was reviewed by Sandor Pongor, Christopher Lee and Mikhail Blagosklonny.
Open peer review
Reviewed by Sandor Pongor, Christopher Lee and Mikhail
Blagosklonny.
For the full reviews, please go to the Reviewers' comments
section.
Background
The p53 protein is called "the guardian of the genome"
because this multifunctional transcription factor, which
regulates cell cycle progression, repair and programmed
cell death in mammals, targets for apoptosis those cells
that accumulate unsustainable DNA damage [1-4]. In
nearly 60% of human cancers, the TP53 gene carries muta-
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tions that are generally thought to abrogate the tumor
suppressor function of p53 [1-4]. However, many inde-
pendent studies have also revealed gain of new biochem-
ical and biological functions as a result of TP53
mutations, suggesting that this gene additionally has
properties of an oncogene [4-10]. Recent reports on
mouse models of the Li-Fraumeni syndrome (LFS), a
familial cancer predisposition syndrome caused by germ-
line p53 mutations, revealed significant changes in the
tumor spectra in mice carrying common p53 mutations,
indicating that gain-of-function in p53 is important for
tumorigenesis [11,12].
This notion has been supported and extended by bioin-
formatic analysis of the tumor-specific mutation spectra
in the TP53 gene which show a highly significant excess of
non-synonymous mutations over the neutral expectation,
suggesting that p53 evolution in tumors is subject to pos-
itive selection [13] as a result of preferential fixation of
missense mutations in p53 [14-16].
However, this apparent positive selection does not neces-
sarily account for the strongly non-uniform distribution
of mutations among the sites in the TP53 gene, i.e., the
existence of hotspots. The presence of hotspots is compat-
ible with either a mutational or a selectional scenario or a
combination thereof [14,17]. A well-characterized case of
apparent mutational origin of hotspots is the preponder-
ance of G>T transitions in the TP53 gene in lung cancers
which is usually perceived as a reflection of the mutagen-
esis specificity of polycyclic carcinogens [18,19]. How-
ever, this paradigm has been challenged on the grounds
that the respective mutations localize predominantly in
highly conserved, functionally important sites of p53
[20]. It is important to determine the relative contribu-
tions of selection and mutation specificity to the hotspot
origin because it has been suggested that mutable nucle-
otide contexts could be used to infer mechanisms of
mutagenesis and thus elucidate key mechanisms of tumor
initiation and progression [18,19]. This type of analysis
has proved informative for somatic hypermutation in
immunoglobulin genes [21,22], some cancer-related
genes in lymphomas [23], and germline mutations in
human disease genes [24,25].
Here we apply three independent tests, accounting for
non-uniform base compositions in synonymous and
non-synonymous sites, to test whether selection makes a
significant contribution to the origin of the hotspots. All
three tests consistently indicate that the hotspots in the
TP53 gene evolve, primarily, via positive selection. By con-
trast, only one, the least conservative test reveals the signa-
ture of positive selection in BRCA1, BRCA2, and p16. The
results of this analysis seem to indicate that positive selec-
tion for gain-of-function in tumor suppressor genes is an
important aspect of tumorigenesis, blurring the distinc-
tion between tumor suppressors and oncogenes.
Results and discussion
Many independent studies have revealed gain of new bio-
chemical and biological functions as a result of TP53
mutations, suggesting that this gene additionally has
properties of an oncogene [4-12]. This notion has been
supported by bioinformatic analysis of the tumor-specific
mutation spectra in the TP53 gene which show a highly
significant excess of missense mutations over the neutral
expectation, suggesting that p53 evolution in tumors is
subject to positive selection [14,15]. In Table 1, we
present an update of this comparison based on the latest
somatic mutation data; the substantial excess of non-syn-
onymous substitutions suggests positive selection [13]
acting on p53 in all tumor types for which sufficient infor-
mation was available.
We developed a simple statistical test (hereinafter NSMC
test, after Non-Synonymous Monte Carlo) that specifi-
cally addressed the dilemma of mutational vs. selectional
origin of the hotspots. This test included comparison of
samples of synonymous and non-synonymous sites
selected such that both the number of sites and the
number of mutations in the samples was the same (Fig.
1). Only positions in which mutations were found were
analyzed. Sites in which both synonymous and non-syn-
onymous substitutions were observed (e.g., third posi-
tions in two-codon series) were analyzed independently
for the two types of substitutions. The NSMC test was
designed to account for differences in the nucleotide com-
positions and the frequencies of substitutions in synony-
mous and non-synonymous sites (non-synonymous sites
were sampled to mimic the nucleotide composition in
synonymous sites). With this normalization, the compar-
ison of the number of hotspots, i.e., sites with at least two
substitutions, between the samples of synonymous and
non-synonymous (designated NSH and NNH, respec-
tively) sites gives a measure of the skewness of the distri-
bution of mutations (Fig. 1). Monte Carlo simulations,
repeated 100,000 times, were used to assess the statistical
significance of differences between the distributions of
hotspots in the synonymous and non-synonymous sites.
Two alternative statistical hypotheses were tested: H0 –
mutational bias (no difference between the distributions
of hotspots in the synonymous and non-synonymous
sites) and H1  – selectional bias (the distributions of
hotspots in the synonymous and non-synonymous sites
are different). The fraction of simulated sets in which
NNH > NSH is the probability P(H1) of the rejection of
H0. Large values of P(H1) (≥ 0.95) indicate that the
hypothesis H0 is rejected and there is a significant excess
of hotspots in non-synonymous sites.Biology Direct 2006, 1:4 http://www.biology-direct.com/content/1/1/4
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Table 1: NSMC and NSCS test results for TP53 somatic mutation spectra (H0: mutational bias; H1: selectional bias)
Sites Mutations Hotspots P(H1)/χ2
Bladder
S y n o n y m o u s 6 18 01 2
Non-synonymous 240 775 110 0.107/13.8
Nonsense 36 85 26 0.038
Brain
Synonymous 20 23 2
Non-synonymous 199 812 98 0.998/11.2
Nonsense 14 32 5 0.015
Breast
Synonymous 77 108 19
Non-synonymous 294 1423 171 0.111/27.3
Nonsense 49 73 27 0.052
Liver
Synonymous 34 43 5
Non-synonymous 199 727 99 0.980/14.4
Nonsense 29 50 16 0.040
Lung
S y n o n y m o u s 5 68 81 7
Non-synonymous 314 1599 191 0.959/17.9
Nonsense 55 170 31 0.042
Pancreas
Synonymous 10 12 1
Non-synonymous 106 215 30 0.049/1.56
Nonsense 10 17 6 0.058
Ovary
Synonymous 20 21 1
Non-synonymous 192 770 99 0.995/15.7
Nonsense 30 71 12 0.012
Prostate
Synonymous 28 38 7
Non-synonymous 114 195 38 0.926/0.72
Nonsense 9 12 2 0.008
Colon
Synonymous 23 28 4
Non-synonymous 173 592 69 1.000/4.4
Nonsense 19 60 5 0.016
Colorectal
Synonymous 25 28 4
Non-synonymous 203 1097 121 0.000/20.3
Nonsense 29 103 12 0.953
Esophagus
Synonymous 25 32 7
Non-synonymous 215 1064 117 0.025/6.26
Nonsense 50 150 27 0.032
Hematopoietic
Synonymous 26 29 3
Non-synonymous 202 723 99 0.037/13.08
Nonsense 20 37 5 0.018
Larynx
Synonymous 8 10 2
Non-synonymous 108 234 42 1.000/0.60
Nonsense 18 24 5 0.007
Mouth
Synonymous 28 41 9
Non-synonymous 176 413 79 0.988/1.59
Nonsense 33 53 10 0.901
Skin
Synonymous 64 136 12
Non-synonymous 248 563 99 0.931/9.94Biology Direct 2006, 1:4 http://www.biology-direct.com/content/1/1/4
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Using the NSMC test, we detected a statistically significant
excess of hotspots in non-synonymous sites in 50% of the
tumors for which extensive mutational data was available
(Table 1). When the data from all tumor types were
pooled, the excess of hotspots in non-synonymous sites
was highly significant: the null hypothesis, i.e., that the
distributions of mutations in the synonymous and non-
synonymous sites were identical, was rejected with P <
0.001 (Table 2). Since we accounted for differences in
nucleotide compositions, mutational biases are not
expected to differ between synonymous and non-synony-
mous positions. Thus, the greater skew of the mutation
distribution in non-synonymous positions should be
viewed as evidence of, primarily, selectional origin of the
hotspots.
This conclusion was further supported by analysis of
mutation spectra after removal of CpG dinucleotides, the
most prominent mutational hotspots in the human
genome [24,25]. Under this test, many hotspots in CpG
sites overlapping arginine, glycine and valine codons were
removed but the selection hypothesis was nevertheless
supported for several tissues and for the combined spec-
trum (Additional file 1). Furthermore, the results of the
NSMC test performed before or after removal of the CpG
sites did not depend on the threshold used for hotspot
identification (Additional file 2).
We also applied the NSMC test to compare the distribu-
tions of hotspots in nonsense and synonymous sites. An
excess of hotspots in nonsense sites would be indicative of
positive selection for loss of p53 function. A significant
excess of hotspots in nonsense sites was detected only in
colorectal cancers as opposed to 8 of the 16 analyzed
tumor types in which hotspots non-randomly associated
with non-synonymous sites were identified (Table 1). The
difference between the excess of hotspots in non-synony-
mous sites and the excess of hotspots in nonsense sites
was statistically significant (P = 0.015 by the Fisher's exact
test). This observation is compatible with the notion that
non-synonymous hotspots in p53 evolve under positive
selection for gain of function.
The procedure used for random sampling of mutations at non-synonymous sites in the NSMC test Figure 1
The procedure used for random sampling of mutations at non-synonymous sites in the NSMC test. Step 1 
includes the selection of a sample of non-synonymous sites such that the number of sites and their base composition were the 
same as in the entire set of synonymous substitutions in the given gene; sampling was performed without replacement. The 
comparison of the number of hotspots, i.e., sites with at least two substitutions, between the samples of synonymous and non-
synonymous sites gives a measure of the skewness of the distribution of mutations (Step 2). Synonymous sites and sampled 
non-synonymous sites are shown by inverse shading, synonymous hotspots are shown in yellow, and simulated non-synony-
mous hotspots are shown in green.
 C           T          C           T 
 C           T          C           T       C 
 CC   A      T          C           T       C 
 CG   A      TT         C           T       C
 CT   A A G  TT    1    C      A    T    2  C      A    T 
AAG GTG GTA TCC   ->   AAG GTG GTA TCC  -> AAG GTG GTA TCC
Observed mutation spectrum         Random sampling of               Random sampling of 
                                                       non-synonymous sites             non-synonymous
                                                                                                        mutations
Nonsense 25 69 12 0.025
Stomach
S y n o n y m o u s 4 46 41 5
Non-synonymous 195 617 88 0.115/1.78
Nonsense 21 52 8 0.029
In the last column, the P-value for the NSMC test (numerator) and the χ2 value for the NSCS test (denominator) are shown along with the NSMC 
test P-value for the hotspots in nonsense sites. The statistically significant values (rejection of H0) are shown in bold type.
Table 1: NSMC and NSCS test results for TP53 somatic mutation spectra (H0: mutational bias; H1: selectional bias) (Continued)Biology Direct 2006, 1:4 http://www.biology-direct.com/content/1/1/4
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We further tested the hypothesis of independence
between the mutation class (hotspot vs. non-hotspot) and
site class (non-synonymous vs. synonymous). The data
for all analyzed spectra were represented as 2 × 2 contin-
gency tables which were analyzed using the χ2 test (here-
inafter NSCS test, after Non-Synonymous Chi-Square).
Using the NSCS test, we observed a significant excess of
hotspots in non-synonymous sites compared to the expec-
tation under the independence hypothesis. Thus, two
independent statistical tests show that, in the spectra of
somatic mutations in the TP53 gene from most tumors,
the hotspots are highly non-randomly associated with
non-synonymous sites. In a direct analogy to the classical
Ka/Ks signature of positive selection [13], this preferential
occurrence of hotspots in non-synonymous positions
indicates that the hotspots result, mostly, from positive
selection for new functions of the p53 protein.
Both the NSMC and the NSCS tests produced opposite
results when applied to the available mutational spectra
of three other tumor suppressor genes, BRCA1, BRCA2,
and p16INK4a (Table 3) [26]. The hypothesis that hotspots
are randomly distributed among synonymous and non-
synonymous sites could not be rejected for these genes.
This observation suggests that p53 might be unique
among tumor suppressors in that its somatic evolution in
many tumors involves intense positive selection for gain
of function. Alternatively, however, it cannot be ruled out
that the available mutation data for the other tumor sup-
pressors is insufficient to detect statistically significant
association of hotspots with non-synonymous sites.
We also developed a third statistical test (hereinafter NSB
test, after Non-Synonymous Binomial) to identify non-
synonymous substitution hotspots (analyzed, for this
purpose, at the level of codons), i.e., those with a statisti-
cally significant excess of non-synonymous substitutions
over the random expectation. The expected numbers of
non-synonymous and synonymous substitutions were
calculated using a Monte-Carlo simulation procedure,
which was repeated 1,000 times for each codon. Each step
involved random shuffling of transitions and transver-
sions among the three positions of a codon. The statistical
significance of the observed excess of the number of the
detected non-synonymous substitution hotspots over the
random expectation was assessed using the binomial test
and the Bonferroni correction for multiple tests.
The NSB test revealed from 1 (p16) to 59 (TP53) hotspots
non-randomly associated with non-synonymous sites in
each of the tumor suppressors (Table 4). Thus, it appears
that positive selection might affect not only somatic evo-
lution of p53 but also that of other tumor suppressors
albeit, seemingly, to a lesser extent. The failure of the
NSMC and NSCS tests to detect the signature of positive
selection in genes other than p53 could be due to the fact
that these tests require a large number of synonymous
substitutions which is currently available only for p53.
Alternatively, however, it cannot be ruled out that synon-
ymous substitutions are underrepresented in the data-
bases for BRCA1, BRCA2, and p16. Such an artifact would
affect the NSB test, potentially resulting in false-positives,
but not the NSMC or the NSCS tests. Expanded compen-
dia of somatic mutations for these genes and thorough
database curation are critical for a reliable assessment of
the contribution of positive selection to their evolution in
tumors. Even the largest available database of somatic
mutations, that for p53, is not large enough for some sta-
tistical experiments. For example, we were unable to apply
our tests to G>T substitutions in lung tumors [18-20]
because only a few unique synonymous G>T substitutions
associated with lung tumors were found in the p53 data-
base, whereas the non-synonymous G>T mutations are
the most frequent type of substitutions in lung tumors
[14,18-20]. Furthermore, more data on somatic muta-
tions is required to explore the effect of nucleotide context
other than that of CpG that was examined here.
It should be emphasized that, although we detected a
highly statistically significant association of non-synony-
mous sites with hospots, in particular, for p53, the results
of the present analysis do not allow us to assign any indi-
vidual mutation to the gain-of-function or loss-of-func-
tion category. Nevertheless, these results can be used for
devising experimental studies of gain-of-function by
tumor suppressors mutated in specific sites (hotspots)
and/or specific tumor types with particularly strong evi-
dence of positive selection.
Conclusion
The previous computational analysis of the tumor-specific
mutation spectra of the TP53 gene has suggested that pos-
itive selection made a substantial contribution to the evo-
lution of this gene during tumorigenesis [14,15]. Here, we
show that positive selection, as opposed to mutational
biases, is, largely, responsible for the formation of
hotspots in the TP53 gene (of course, this does not rule
out the existence of true mutational hotspots and their
substantial role in tumorigenesis; we only show that such
hotspots are in the minority). This finding is compatible
with the previous observations that hotspots are located
primarily in highly conserved, functionally important
regions of p53 [14,17]. Together, the results of computa-
tional analyses of the mutational spectra strongly support
the crucial role of gain-of-function in the tumorigenic
evolution of p53, which agrees with the results of several
experimental studies [4-10], in particular, the recent work
on mouse models of the Li-Fraumeni syndrome [11,12].
It has been shown that hotspots are tumor-specific and,
furthermore, include both residues that are directlyBiology Direct 2006, 1:4 http://www.biology-direct.com/content/1/1/4
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involved in DNA-binding and residues that are important
for maintaining the conformation of the p53 protein [14].
Thus, along with loss of function mutations, tumorigene-
sis might involve positive selection for a diverse set of
novel activities of p53. The present analysis also yielded
preliminary evidence of the role of positive selection in
the evolution of BRCA1, BRCA2, and p16, suggesting that
mutational gain-of-function in tumor suppressors might
be a widespread and important aspect of tumorigenesis
and blurring the boundary between tumor suppressors
and oncogenes.
Materials and methods
The TP53 mutation data were from the IARC database
[27]. Sixteen tumor types were analyzed (the IARC "short
topology" keyword = "BLADDER, BRAIN, BREAST, LIVER,
LUNG, PANCREAS, OVARY, PROSTATE, COLON,
COLORECTAL, ESOPHAGUS, HEMATOPOIETIC, LAR-
YNX, MOUTH, SKIN, STOMACH"). The p16, BRCA1 and
the  BRCA2  mutation data were from the databases of
mutation spectra in the p16 gene [28] and the BRCA1 and
BRCA2 genes [29]. The statistical tests were implemented
as ad hoc programs written in C++ or Perl.
Reviewers' comments
Reviewer's report 1
Sandor Pongor, International Centre for Genetic Engineering
and Biotechnology, Padriciano 99, I-34012, Trieste, Italy
Detecting positive selection at the DNA sequence level is
of substantial interest in view of the role it may play in
pathogenic events. Glazko and coworkers show, using
three statistical tests developed for the purpose, that the
mutational hotspots of the TP53 gene evolve by positive
selection. In view of the general interest of the topic I
sought the advice of Dr. Lawrence Banks who is a biologist
working on p53 mutations. We both felt that the calcula-
tions are thoroughly planned and the results support the
main message of the paper.
The presentation of the paper could however be improved
with special respect to the wide audience of Biology
Direct. The most important criticism is that p53 muta-
tions can lead both to inactivation and/or to GOF type
changes, and these two groups may need to be analyzed
separately. Currently, the reader may not see clearly if pos-
itive selection was found only in the case of GOF-type
mutations or also in the case of inactivating mutations.
Author response: We agree that it should be stated with full
clarity that both gain-of-function and loss-of-function muta-
tions in tumor suppressors, in particular, p53, are important.
Therefore such changes have been made in several places in the
manuscript; in particular, see the last paragraph in the Results
and Discussion section.
Minor points:
- In the Background section it might be useful to add 1) a
brief description of mutation types found in p53 as well
as their biological roles; and 2) a paragraph describing the
mathematical approaches to detecting positive selection.
These sections may help the reader in understanding what
has been done and what is being accomplished in this
work.
Table 3: The NSMC and NSCS test results for BRCA1, BRCA2, 
and p16 genes
Class ID Sites Mutations Hotspots P(H1)/χ2
BRCA1
Synonymous 33 142 16
Non-synonymous 356 1842 170 0.204/0.006
Nonsense 141 704 74 0.079
BRCA2
Synonymous 55 103 20
Non-synonymous 797 4871 352 0.071/1.2
Nonsense 179 844 79 0.018
p16
Synonymous 40 63 13
Non-synonymous 171 321 65 0.388/0.423
Nonsense 18 162 14 0.070
The data for combined spectra from all tumor types are shown. Other 
designations are as in Table 1.
Table 2: Combined NSMC and NSCS test results for the TP53 
somatic mutations spectra
Class ID Sites Mutations Hotspots P(H1)/χ2
Class Ia
Synonymous 157 390 76
Non-synonymous 527 5710 385 0.990/33.4
Nonsense 78 529 59 0.023
Class IIb
Synonymous 172 391 97
Non-synonymous 495 6109 379 0.991/25.4
Nonsense 72 629 55 0.018
Class IIIc
Synonymous 217 781 151
Non-synonymous 617 11819 474 0.994/4.47
Nonsense 88 1158 76 0.011
a Class I: combined mutational spectrum of the tumor types for 
which H0 is rejected in comparison of synonymous vs. non-
synonymous substitutions:brain, liver, lung, colon, mouth, larynx, 
ovary and skin.
b Class II: combined mutational spectrum of the tumor types for 
which the test did not find enough evidence, probably, because of the 
small sample size: bladder, breast, prostate, esophagus, colorectal, 
hematopoietic, stomach, and pancreas.
c Class III: combined Class I and Class II spectra.
Other designations are as in Table 1.Biology Direct 2006, 1:4 http://www.biology-direct.com/content/1/1/4
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Author response: We decided not to expand the Background
section because both issues are already addressed there, even if
briefly, and the reader interested in methods for detecting posi-
tive selection is referred to Ref. [13].
- It may be useful to carry out the statistics on subgroups
(GOF or inactivation)
Author response: Some statistics on this point is available in
Ref. [16] (Table 1). However, it has to be realized that,
although we detect the statistical excess of non-synonymous over
synonymous substitutions, the tests describe here, by themselves,
do not allow us to assign an individual substitution to the gain-
of-function or loss of function category. Again, an attempt to
address this issue is given in Ref. [16]but the number of muta-
tions for which the distinction could be made is quite small. We
make comments to that effect in the revised discussion.
- In order to show the strength of the statistical methods
presented here it might be useful to consider tests similar
to those described by Jianzhi Zhang (Mol. Biol. Evol.
21(7): 1332–1339, 2004).
Author response: The statistical analysis presented here was
done within a very different conceptual framework from that
described by Zhang (maximum likelihood models). The present
tests employed the multiple test (Bonferroni) correction and,
accordingly, were highly conservative.
Reviewer's report 2
Christopher Lee, Department of Chemistry, University of Cali-
fornia-Los Angeles, Los Angeles, CA, USA
This paper extends the authors' previous work indicating
evidence of positive selection in p53 "hotspot" mutations,
to show that non-synonymous mutations show a signifi-
cantly greater tendency to cluster (in "hotspots") than do
synonymous mutations, even when some mutational
biases are taken into account. This work addresses an
important biomedical question, and provides an advance,
albeit incremental. I do have some questions which might
benefit from further analysis by the authors:
1. Both in the abstract and introduction, the authors
emphasize the importance of taking into consideration
the effect of "nucleotide context" on mutational bias, as a
motivation for this study. However, as I understand it, this
study takes into consideration nucleotide composition
(i.e. frequency of single nucleotides), not nucleotide con-
text (e.g. frequency of nucleotide triplets, to consider the
effect of one adjacent nucleotide on either side of the
nucleotide under study). Since nucleotide context can
have large effects on mutation rate (e.g. CpG effects), this
is an important issue. For the very reasons that the authors
articulated in their Introduction, many readers will expect
direct tests of whether nucleotide context affects the
authors' results.
The difficulty, of course, is that it is harder to match nucle-
otide context (e.g. triplet frequencies, 64 different num-
bers) than nucleotide composition (just 4 numbers). The
NSMC procedure would probably not be able to construct
samples with matching triplet frequencies, without some
modifications. One possible solution would be to include
ALL sites (including unmutated sites, instead of just sites
where mutations were observed) in the analysis. First,
generate a random sample of synonymous sites (a specific
number of sites, with a specific triplet profile, and a spe-
cific number of observed mutations).
Now generate a random sample of non-synonymous sites
of the same size, with the same triplet profile. Finally, gen-
erate equal-sized random samples of mutations from each
set of sites, and analyze the number of "hotspots" as in the
NSMC method. Including non-mutated sites in this sam-
pling process should make it possible to match the triplet
profiles between the syn vs. non-syn samples, and I don't
see a reason why non-mutated sites should be excluded.
If such analysis is practical I think it could greatly
strengthen the paper, by directly addressing the question
of nucleotide context. At any rate, the existing analysis in
the manuscript should be clearly described as testing
"nucleotide composition" not "nucleotide context", and
the difference between these should be emphasized. The
authors should point out that even if composition is con-
trolled for, nucleotide context could have large effects on
mutation rate, so the current results should be interpreted
with some caution.
Author response: The CpG effects have been accounted for in
the NSMC test; to emphasize this, we mention this control in
the revised abstract. However, the currently available data on
somatic mutations is insufficient to examine other, subtler
effects of the nucleotide context. As for including non-mutated
Table 4: Hotspots non-randomly associated with non-
synonymous sites in tumor suppressor genes according to the 
NSB test
Gene Total number of 
codons
Number of non-synonymous 
hotspots
TP53 394 59
BRCA
1
1864 12
BRCA
2
3419 27
p16 157 1
The hotspots are listed in Additional file 3Biology Direct 2006, 1:4 http://www.biology-direct.com/content/1/1/4
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sites, we were concerned that this approach could lead to uncon-
trollable increase in the error rate due to the different and
unknown intrinsic mutation rates of different sites.
2. The NSMC analysis, while conceptually simple, needs
to be described in more detail, in the Methods section.
Currently, there is only an outline of NSMC, presented in
the Results section, which leaves out many details (e.g.
sampling with replacement or without replacement? I
assume the latter), such that one could not replicate the
calculation with any confidence that equivalent results
would be obtained from the same input data.
Author response: Indeed, sampling without replacement was
employed, and this is mentioned in the revised legend to Figure
1. Otherwise, however, we felt that the description of the test
was sufficient for reproduction.
3. The manuscript frequently uses the term "positive selec-
tion", in a way that sometimes seems like a catch-all name
for any significant divergence from the purely "muta-
tional" process represented by synonymous sites. This
may confuse readers who think of positive selection in
terms of the very specific meaning Ka/Ks > 1, since that is
not what this paper shows. Instead, the NNH>NSH "more
hotspots" criterion gets at a somewhat different issue,
namely the clustering of observed mutations at certain
sites ("hotspots").
First, it should be noted that such clustering could be pro-
duced without Ka/Ks>1. For example, if most codons had
Ka/Ks = 0.1, and a few sites had Ka/Ks = 1, this also could
give rise to more "hotspots" compared with the synony-
mous sample (where no variability in selection occurs
from site to site). Indeed, even if Ka/Ks = 1 everywhere, the
fact that there are typically twice as many non-synony-
mous mutations than synonymous mutations at each
codon could in principle give NNH>NSH. I think the
authors should address this issue in the manuscript, either
by providing control tests showing that their results can-
not be explained by such models, and/or by mentioning
such issues in the Discussion.
Second, the authors may want to replace a number of
occurrences of the phrase "positive selection" with some-
thing more precise for their results, e.g. "selection for non-
synonymous mutations at specific sites (hot spots), rela-
tive to their less frequent occurrence at other non-synony-
mous sites or at synonymous sites"; or just "evidence of
selective pressure at hotspots". When the authors really
want to use the phrase "positive selection", it would be
useful to cite direct evidence that Ka/Ks > 1 for at least a
subset of the sites.
Author response: We already know that, at least in the case
of somatic mutations of p53, Ka/Ks >> 1 (Table 1and Ref.
[14]) which implies positive selection in the traditional sense.
In this paper, we addressed a specific issue of origin of hotspots
using different tests, within the "selection vs. mutation" frame-
work. We believe that the NSB test adequately tests the hypoth-
esis that "...Ka/Ks > 1 for at least a subset of the sites".
4. Since I'm not in the p53 field, it's unclear to me how
cancer researchers can make use of the specific data pre-
sented in this paper. Perhaps the authors could add some
further discussion of this to the paper.
Author response: The last paragraph of the revised Results
and Discussion section addresses this issue.
Reviewer's report 3
Mikhail Blagosklonny, Cancer Center, Ordway Research Insti-
tute, Albany, NY, USA
This study has demonstrated a selective advantage for hot
spot p53 mutants compared with rare mutants. This has a
biological meaning. p53 proteins form tetramers. Mutant
p53 can either inactivate wt p53 or complement mutant
p53, depending of particular mutation. Also, mutant p53
interacts with p63 and p73, thus modulating their func-
tions. Similarly, the distinction between tumor suppres-
sors and oncogenes might be blurred for p63 and p73, see:
Mills AA. p63: oncogene or tumor suppressor? Curr Opin
Genet Dev. 2005 Dec 13; in press.
Author response: Unfortunately, large collections of muta-
tions are unavailable for either p63 or p73.
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